Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials-Reference-Cited by-同舟云学术

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

Published:2016-06-10 Issue:1 Volume:78 Page:167-171
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Bilen Mehmet Asim,Patel Amy,Hess Kenneth R.,Munoz Javier,Busaidy Naifa L.,Wheler Jennifer J.,Janku Filip,Falchook Gerald S.,Hong David S.,Meric-Bernstam Funda,Habra Mouhammed Amir,Naing Aung

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3073-z.pdf

Reference22 articles.

1. Brown RL (2011) Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol 6(4):217–226. doi: 10.1007/s11523-011-0197-2

2. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1):81–83. doi: 10.1093/jnci/djk008

3. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17(4):351–355. doi: 10.1089/thy.2006.0308